Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013 Apr; 129(1):86-91.
View in:
PubMed
subject areas
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Angiogenesis Inhibitors
Angiogenesis Inhibitors
DNA, Neoplasm
DNA, Neoplasm
Fallopian Tube Neoplasms
Fallopian Tube Neoplasms
Female
Female
Glial Cell Line-Derived Neurotrophic Factor
Glial Cell Line-Derived Neurotrophic Factor
Humans
Humans
Indoles
Indoles
Middle Aged
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Recurrence, Local
Niacinamide
Niacinamide
Oligonucleotides
Oligonucleotides
Ovarian Neoplasms
Ovarian Neoplasms
Peritoneal Neoplasms
Peritoneal Neoplasms
Protein Kinase Inhibitors
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor A
authors with profiles
Michael A Gold
Robert S Mannel